 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| ASKG915 / Aosaikang Pharma
Enrollment open, Trial primary completion date, Metastases: A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. (clinicaltrials.gov) - Aug 9, 2023
P1, N=104, Recruiting, Sponsor: AskGene Pharma, Inc.
Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2024 --> Mar 2024
- ||| ASKG915 / Aosaikang Pharma
New P1 trial, Metastases: A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. (clinicaltrials.gov) - May 22, 2023
P1, N=104, Not yet recruiting, Sponsor: AskGene Pharma, Inc.
- | ASKG915 / Aosaikang Pharma
#AskGene Announces Submission of #IND to #FDA for #ASKG915 https://t.co/bj905abDD6 (Twitter) - Nov 21, 2022
- || ASKG315 / Aosaikang Pharma, ASKG915 / Aosaikang Pharma
#AskGene Presents Latest Results on #ASKG315 and #ASKG915 at #SITC22 https://t.co/srKNP2Y4tE (Twitter) - Nov 16, 2022
- ASKG915 / Aosaikang Pharma
ASKG915 - An Anti-PD-1 Antibody-IL-15 Prodrug Fusion Molecule with Enhanced Therapeutic Potentials (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_1491;
To our knowledge, ASKG915 is the first anti-PD-1 antibody-IL-15 prodrug fusion molecule moving into clinical development. Ethics Approval The use of the animals in the studies have been approved by the ethics committees of the research contract organizations (CRO).